Showing papers by "William N. Washburn published in 2004"
TL;DR: A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human beta3 adrenergic receptor agonist activity, leading to the identification of BMS-201620, a potent beta3 full agonist.
18 citations
Patent•
23 Jan 2004TL;DR: In this paper, novel thyroid receptor ligands are provided having the general Formula (I) wherein X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11, are as defined herein.
Abstract: Novel thyroid receptor ligands are provided having the general Formula (I) wherein X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11, are as defined herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
9 citations
Patent•
23 Jan 2004TL;DR: Novel thyroid receptor ligands are provided having the general formula I wherein X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12. and R13 are as defined herein this paper.
Abstract: Novel thyroid receptor ligands are provided having the general formula I wherein X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12. and R13 are as defined herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
9 citations
Patent•
23 Jan 2004
TL;DR: In this article, a procedure for prevention, inhibition, traitement, or traitement of maladies or troubles associes a un dysfonctionnement metabolique or dependant on l'expression d'un gene regule par T3, consistant a administrer un compose selon l'invention dans une quantite therapeutique efficace.
Abstract: L'invention concerne des ligands de recepteur thyroidien representes par la formule (I) dans laquelle X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 et R13 ont la signification donnee dans le descriptif. L'invention concerne par ailleurs un procede de prevention, d'inhibition ou de traitement de maladies ou de troubles associes a un dysfonctionnement metabolique ou dependant de l'expression d'un gene regule par T3, consistant a administrer un compose selon l'invention dans une quantite therapeutique efficace.